Synthetic heparin derivatives as new anticoagulant drugs

Drug Discovery Today

Volumn 10, Issue 11, 2005, Pages 769-779

  De Kort, Martin ^a   Buijsman, Rogier C ^a   Van Boeckel, Constant A A ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA N (2 NAPHTHALENESULFONYL)GLYCYL DEXTRO 4 AMINOPHENYLALANYLPIPERIDINE; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DESULFATOHIRUDIN; DRUG DERIVATIVE; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ORG 31550; ORG 39913; ORG 42675; PARACETAMOL; PARACETAMOL DERIVATIVE; SANORG 123781; SR 123781; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ACUTE RESPIRATORY TRACT DISEASE; ARTERY OCCLUSION; BINDING AFFINITY; CLINICAL TRIAL; COMPLEX FORMATION; CRYSTAL STRUCTURE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IC 50; INFECTION; INFLAMMATION; INHIBITION KINETICS; LUNG EMBOLISM; MOLECULAR MIMICRY; MOLECULAR MODEL; NONHUMAN; REVIEW; SIDE EFFECT; THROMBOEMBOLISM;

ANTICOAGULANTS; FACTOR XA; HEPARIN; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOCYTOPENIA;

EID: 19744372264     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03457-4     Document Type: Review

References (76)

1. Messmore H.L. Jr Heparin to pentasaccharide and beyond: the end is not in sight Semin. Thromb. Hemost. 30 Suppl. 1 2004 81 88
2. Linhardt R.J. Heparin: structure and activity J. Med. Chem. 46 2003 2551 2554
3. Petitou M. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site Biochimie 85 2003 83 89
4. Sinaÿ P. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III Carbohydr. Res. 132 1984 C5 C9
5. Petitou M. Synthesis of heparin fragments Carbohydr. Res. 147 1986 221 236
6. van Boeckel C.A.A. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin J. Carbohydr. Chem. 4 1985 293 321
7. van Boeckel C.A.A., Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew. Chem., Int. Ed. Engl. 32 1993 1671 1690
8. Samama M-M. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux) Thromb. Res. 109 2003 1 11
9. Bauer K.A. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors Cardiovasc. Drug Rev. 20 2002 37 52
10. Turpie A.G.G. Fondaparinux: a factor Xa inhibitor for antithrombotic therapy Expert Opin. Pharmacother. 5 2004 1373 1384
11. Lisman T. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux J. Thromb. Haemost. 1 2003 2368 2373
12. Bijsterveld N.R. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers Br. J. Haematol. 124 2004 653 658
13. van Boeckel C.A. A mechanism for heparin-induced potentiation of antithrombin III Nat. Struct. Biol. 1 1994 423 425
14. van Boeckel C.A.A. Glycosaminoglycans: synthetic fragments and their interaction with serine protease inhibitors Pure & Appl. Chem. 67 1995 1663 1672
15. Johnson D.J.D., Huntington J.A. The influence of hinge region residue Glu-381 on antithrombin allostery and metastability J. Biol. Chem. 279 2004 4913 4921
16. Quinsey N.S. Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide J. Biol. Chem. 277 2002 15971 15978
17. Jin L. The anticoagulant activation of antithrombin by heparin Proc. Natl. Acad. Sci. U. S. A. 94 1997 14683 14688
18. Johnson D.J.D., Huntington J.A. Crystal structure of antithrombin in a heparin-bound intermediate state Biochemistry 42 2003 8712 8719
19. Huntington J.A. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis J. Thromb. Haemost. 1 2003 1535 1549
20. van Boeckel C.A.A. Synthesis of a potent antithrombin activating pentasaccharide: a new heparin-like fragment containing two-3-O-sulfated glucosamines Tetrahedron Lett. 29 1988 803 806
21. Carrie D. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216 Blood 84 1994 2571 2577
22. Herbert J.M. Biochemical and pharmacological properties of SanOrg 34006, a potent and long-acting synthetic pentasaccharide Blood 91 1998 4197 4205
23. Desai U.R. Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites Biochemistry 37 1998 13033 13041
24. Desai U.R. Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin J. Biol. Chem. 273 1998 7478 7487
25. Turpie A.G.G. New pentasaccharides for the prophylaxis of venous thrombolism: clinical studies Chest 124 2003 371S 378
26. The PERSIST investigators A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation J. Thromb. Haemost. 2 2004 47 53
27. Olson S.T., Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb. Hemost. 20 1994 373 409
28. Petitou M. First synthetic carbohydrates with the full anticoagulant properties of heparin Angew. Chem., Int. Ed. Engl. 37 1998 3009 3014
29. Duchaussoy P. Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation' Carbohydr. Res. 317 1999 63 84
30. Petitou M., van Boeckel C.A.A. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem., Int. Ed. Engl. 43 2004 3118 3133
31. Grootenhuis P.D.J. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity Nat. Struct. Biol. 2 1995 736 739
32. Li W. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin Nat. Struct. Mol. Biol. 11 2004 857 862
33. Dementiev A. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity Nat. Struct. Mol. Biol. 11 2004 863 867
34. Petitou M. Experimental proof for the structure of a thrombin-inhibiting heparin molecule Chemistry 7 2001 858 873
35. Westerduin P. Synthesis of tailor-made glycoconjugates showing ATIII-mediated inhibition of blood coagulation factors Xa and thrombin Angew. Chem. Int. Ed. Engl. 35 1996 331 333
36. Petitou M. New synthetic heparin mimetics able to inhibit thrombin and factor Xa Bioorg. Med. Chem. Lett. 9 1999 1155 1160
37. Petitou M. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics Bioorg. Med. Chem. Lett. 9 1999 1161 1166
38. Vogel G.M.T. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities Thromb. Haemost. 84 2000 611 620
39. Dreef-Tromp C.M. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers Bioorg. Med. Chem. Lett. 8 1998 2081 2086
40. Petitou M. Synthesis of thrombin-inhibiting heparin mimetics without side effects Nature 398 1999 417 422
41. Bal dit Sollier C. Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis J. Thromb. Haemost. 2 2004 925 930
42. Herbert J-M. SR123781A, a synthetic heparin mimetic Thromb. Haemost. 85 2001 852 860
43. Stueber, W. et al. (1994) Inhibition of thrombin by derivatives of the dipeptide aspartic acid-amidinophenylalanine. Proceedings of the 13th American Peptide Symposium, 20-25 June 1993, Edmonton, Alberta, Canada, 643-645
44. Stuber W. Preparation and evaluation of PEG-bound thrombin inhibitors based on 4-amidinophenylalanine Pept. Res. 8 1995 78 85
45. Kaiser B. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor Biomed. Biochim. Acta 44 1985 1201 1210
46. Steinmetzer T. Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines Eur. J. Biochem. 265 1999 598 605
47. Buijsman R.C. Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying dual antithrombotic action Bioorg. Med. Chem. Lett. 9 1999 13 18
48. Vogel G.M. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity J. Thromb. Haemost. 1 2003 1945 1954
49. Flather M.D. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomised trial Eur. Heart J. 21 2000 1473 1481
50. Merlini P.A. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris Arterioscler. Thromb. Vasc. Biol. 20 2000 2162 2171
51. Becker R.C. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential J. Am. Coll. Cardiol. 34 1999 1020 1027
52. Bijsterveld N. Rebound thrombin generation after heparin therapy in unstable angina: a randomized comparison between unfractionated and low-molecular weight heparin J. Am. Coll. Cardiol. 39 2001 811 817
53. Lefkovits J., Topol E.J. Direct thrombin inhibitors in cardiovascular medicine Circulation 90 1994 1522 1536
54. Hashimoto M. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles Thromb. Haemost. 87 2002 110 113
55. Hogg P.J., Jackson C.M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc. Natl. Acad. Sci. U. S. A. 86 1989 3619 3623
56. Weitz J.I. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors J. Clin. Invest. 86 1990 385 391
57. Avci F.Y. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties Curr. Pharm. Des. 9 2003 2323 2335
58. Poletti L., Lay L. Chemical contributions to understanding heparin activity: synthesis of related sulfated oligosaccharides Eur. J. Org. Chem. 16 2003 2999 3024
59. Codée J.D.C. Probing the heparin-antithrombin III interaction using synthetic pentasaccharides bearing positively charged groups Eur. J. Org. Chem. 23 2002 3954 3965
60. Gunnarsson G.T., Desai U.R. Designing small, nonsugar activators of antithrombin using hydropathic interaction analyses J. Med. Chem. 45 2002 1233 1243
61. Basten J.E.M. Preparation of oligosaccharide conjugates of NAPAP or NAPAP-analogs as antithrombotics PCT Int. Appl. 1999 36 WO 9965934
62. Van Boeckel C.A.A. Preparation of sulfate-containing pentasaccharide uronates as antithrombotic agents PCT Int. Appl. 2001 33 WO 2001042262
63. Warkentin T.E. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin N. Engl. J. Med. 332 1995 1330 1335
64. Nand S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution Am. J. Hematol. 56 1997 12 16
65. Warkentin T.E. Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood 96 2000 1703 1708
66. Warkentin T.E. An overview of the heparin-induced thrombocytopenia syndrome Semin. Thromb. Hemost. 30 2004 273 283
67. Kelton J.G. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4 Blood 83 1994 3232 3239
68. Greinacher A. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia Thromb. Haemost. 74 1995 886 892
69. Weitz J.I. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors 86 J. Clin. Invest. 1990 385 391
70. Kalus J.S., Caron M.F. Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin Expert Opin. Investig. Drugs 13 2004 465 477
71. Direct Thrombin Inhibitor Trialists Collaborative Group Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data Lancet 359 2002 294 302
72. Reers M. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine J. Enzyme Inhib. 9 1995 61 72
73. Markwardt F., Walsmann P. The reaction between hirudin and thrombin Hoppe Seylers Z. Physiol. Chem. 312 1958 85 98
74. Rydel T.J. The structure of a complex of recombinant hirudin and human alpha-thrombin Science 249 1990 277 280
75. Adang A.E.P. Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics J. Med. Chem. 45 2002 4419 4432
76. Lefkovits J., Topol E.J. Direct thrombin inhibitors in cardiovascular medicine Circulation 90 1994 1522 1536